Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.69 USD | +4.38% |
|
+5.60% | -4.97% |
18/06 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
11/06 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.97% | 2.38B | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target